- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03059277
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial to determine the efficacy of intravitreal aflibercept (IAI) administered in a treat and extend fashion in eyes that have persistent centered involved diabetic macular edema despite at least 4 intravitreal injections of ranibizumab 0.3mg over 24 weeks prior to enrollment. Patients will receive intravitreal injections of aflibercept (2mg/0.05cc) at baseline and monthly until an eye has reached stability defined as: < 10% change in the Spectral Domain Optical Coherence Tomography (SD OCT) central retinal thickness (CRT) reading from the previous 2 visits (can include baseline) and less than a 5 letter decrease in Best Corrected Visual Acuity (BCVA) from best BCVA from prior visits. Once an eye has reached stability criteria, a treat and extend protocol will be used and treatment will be rendered on every visit. The duration between treatments will be extended by 2 weeks from the last visit if SD OCT extension criteria are met: < 10% change in CRT over 2 consecutive visits and < 5 letter decrease in BCVA from baseline
If at any return visit subretinal and/or intraretinal fluid recurs that causes the CRT to increase by > 10 % from its lowest level in the previous 2 consecutive visits, or CRT increases by < 10% due to subretinal and/or intraretinal fluid but is associated with a decrease of BCVA of > 5 letters from baseline then the eye will receive IAI and the treatment interval will be decreased by 1 week. If the eye has not improved or worsened for at least 2 consecutive visits and the SD OCT central subfield thickness is ≥ 300 microns or visual acuity is worse than 20/20, the following will be done:
Prior to the 24-week visit, an injection will be given. At and after the 24-week visit, an injection will be given and modified grid laser can be given at the discretion of the investigator within 7 days of IAI based on rescue criteria
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- Charlotte Eye Ear Nose and Throat Associates, PA
-
Statesville, North Carolina, United States, 28677
- Charlotte Eye Ear Nose and Throat Associates, PA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years with type 1 or type 2 diabetes
- Best Corrected Visual Acuity (by ETDRS) letter score in study eye ≤ 85 and ≥24 (approximate Snellen equivalent 20/20 to 20/320)
- Central retinal thickness on SD OCT at baseline visit of > 300 microns using Heidelberg Spectralis with definite evidence of intraretinal or subretinal fluid due to diabetic retinopathy in the CSF.
- Patients must have received at least four intravitreal ranibizumab 0.3 mg injections within 24 weeks prior to screening and failed to have had complete resolution of intraretinal or subretinal fluid on SD OCT and a CRT > 300 microns using Heidelberg Spectralis
Exclusion Criteria:
- Laser photocoagulation (panretinal or macular) in the study within 90 days of baseline
- Active high risk proliferative diabetic retinopathy (PDR)
- History of intravitreal corticosteroids within 4 months of baseline
- History of intravitreal bevacizumab within 24 weeks of baseline
- History of idiopathic or autoimmune uveitis in the study eye
- Cataract surgery in the study eye within 90 days of baseline
- Any intraocular surgery within 90 days of baseline
- Vitreomacular traction or epiretinal membrane in the study eye that is thought to affect vision
- Evidence of active infection in either eye
- Uncontrolled glaucoma in the study eye defined as a pressure of > 25 mmHg on maximal medical therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravitreal Aflibercept
Intravitreal Aflibercept Injection (IAI)
|
Intravitreal Aflibercept 2mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Central Subfield Thickness (CST)
Time Frame: 52 weeks
|
Percentage of patients who experience a > 10% decrease in mean Central Subfield Thickness (CST) from baseline or whose CST < 300 microns at 52 weeks.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Visual Acuity
Time Frame: 52 weeks
|
Mean change in Best Corrected Visual Acuity
|
52 weeks
|
Change in Central Subfield Thickness (CST)
Time Frame: 52 weeks
|
Mean change in CST on SD OCT compared to baseline
|
52 weeks
|
Number of Intravitreal Injections
Time Frame: 52 Weeks
|
Mean number of injections from baseline
|
52 Weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Andrew N Antoszyk, MD, Charlotte Eye Ear Nose and Throat Assciates, PA
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VGFTe-DME-1432
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on Intravitreal Aflibercept
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Innovent Biologics (Suzhou) Co. Ltd.SuspendedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationChina
-
M. Ali Khan, MDUniversity of California, Los Angeles; Southeastern Retina Associates; Eye Associates...RecruitingProliferative Vitreoretinopathy | Retinal Detachment With Multiple Breaks, Unspecified EyeUnited States
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Genentech, Inc.; Regeneron PharmaceuticalsCompletedDiabetic Macular EdemaUnited States
-
Retina Clinic, Sao Paulo, BrazilFederal University of São PauloCompletedDiabetic Macular Edema | Age Related Macular Degeneration | Central Retinal Vein Occlusion With Macular Edema | Branch Retinal Vein Occlusion With Macular EdemaBrazil
-
Panhandle Eye Group, LLPCompletedDiabetic RetinopathyMexico
-
Southeast Retina Center, GeorgiaRegeneron PharmaceuticalsUnknownNeovascular Polypoidal Choroidal VasculopathyUnited States
-
Kim's Eye HospitalBayerRecruitingRetinal Angiomatous ProliferationKorea, Republic of